Immunotherapy generally is a treatment in which cells in the human body are recoded and injected back into a patient in order to train the patient’s immune system to fight various diseases such as cancer. Cancer centers such as Hackensack Meridian Health’s John Theurer Cancer Center and Memorial Sloan Kettering, and pharmaceutical giants including Celgene and Johnson & Johnson have made big bets on the treatment.
The program will combine lectures and hands-on training to introduce the newest approaches and technologies applied to the development and production of these innovative therapies.
“The pharmaceutical industry faces formidable challenges as it adapts to the new culture of biotechnology,” said NJII CEO Donald Sebastian, during NJII’s Annual Innovation Summit in Newark on March 15. “This training initiative demonstrates NJII’s commitment to advance cell and gene therapy manufacturing and processing innovation.”